Gurobi Releases Annual State of Mathematical Optimization Report
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the release of its annual State of Mathematical Optimization Report. The report sheds light on how organizations across industries are leveraging mathematical optimization, while also exploring the broader trends shaping the industry.
The report is based on survey responses from 440 commercial users of mathematical optimization. The findings indicate that interest in mathematical optimization is continuing to grow, with 93% saying it is either “gaining traction” or “remaining steady” among decision-makers in their organization.
Other key findings include:
- Growing Demand for Optimization Expertise: Nearly all respondents (98%) reported that their organization’s operations research teams were growing or remaining steady—a 5% increase from last year.
- Growing Reliance on Optimization:84% of respondents said their work in mathematical optimization is “mission-critical” to their organization.
- Integration with Machine Learning Remains High: 81% reported that their organization currently combines machine learning with mathematical optimization for at least one project, which is consistent with last year’s findings.
- Diverse Applications Across Industries: The top use cases reported by respondents include planning (55%), operational applications (45%), production planning (42%), and supply chain planning (41%), demonstrating optimization’s versatility.
- Increased Overlap Between Optimization and Data Science: 55% of respondents report collaborating with data scientists on a daily or weekly basis, reflecting a rise in cross-functional collaboration.
“The findings from this year’s survey highlight the continued growth and prominence of mathematical optimization across a wide range of industries,” said Duke Perrucci, CEO of Gurobi. “As more organizations recognize its potential to solve strategic and operational challenges, we’re excited to see its adoption expand into even more areas.”
The State of Mathematical Optimization report is available for download on the Gurobi website.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, customers can make optimal business decisions in seconds. From workforce scheduling and portfolio optimization to supply chain design and everything in between, Gurobi identifies the optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations in the Americas, Europe, and Asia. It serves customers in nearly all industries, including organizations like SAP, Air France, and the National Football League. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129084615/en/
Contacts
Kaelyn Barron
(909) 359 4782
Gurobi Optimization
kaelyn.barron@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celonis Appoints Daniel Brown as Chief Product Officer to Drive Platform Innovation and Growth3.2.2025 17:38:00 EET | Press release
Celonis, the global leader in Process Mining and Process Intelligence, today announced the appointment of Daniel Brown as Chief Product Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203013107/en/ Dan Brown joins Celonis as Chief Product Officer (Photo: Business Wire) “I am thrilled to join Celonis,” said Brown. “I’ve long admired its pioneering products, rapid innovation, and ability to deliver transformative results for customers and partners. What impresses me most is how the Celonis platform connects companies to their processes, teams to each other and AI to the business. I’m eager to contribute to this incredible journey and help shape the future of Process Intelligence.” “Dan brings a wealth of product strategy and leadership experience to Celonis,” said Alex Rinke, co-Founder and co-CEO at Celonis. “As the market leader in Process Intelligence, we are constantly pushing the boundaries of what our platform
Michael Bowes Appointed Executive Vice President, Chief People Officer, The Estée Lauder Companies3.2.2025 17:10:00 EET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced that Michael Bowes has been appointed Executive Vice President, Chief People Officer, effective April 1, 2025, reporting directly to President and Chief Executive Officer, Stéphane de La Faverie. As the first company executive to hold the title of Chief People Officer, Michael will oversee all areas of Global Human Resources, including talent management, career development and organizational design, and, with a people-focused mindset, will drive the organization forward by focusing on continuous culture building. “Michael is a dynamic leader with a deep passion for people and culture,” said Stéphane. “His strategic vision, commitment to talent development, and ability to foster collaboration across our global organization make him the ideal leader to shape the future of our workforce. Michael’s promotion to EVP, Chief People Officer, reflects his exceptional track record and his unwavering commitment to making ELC a place where
Innovaderm Research, a Dual Focus CRO, Appoints Jeff Smith as New CEO3.2.2025 16:00:00 EET | Press release
Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients. Jeff brings nearly 30 years of experience in the pharmaceutical and CRO industry, most recently as CEO of another therapeutically focused CRO, where he has distinguished himself through his exceptional leadership, strategic vision, and ability to innovate. His expertise spans global operations, growth management, and fostering a collaborative and high-performing corporate culture. Jeff’s strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles. Jeff is well-equipped to lead Innovaderm into its next phase of growth and innovation.
ELIQUENT Life Sciences Announces: Rob Wojciechowski Named Chief Operations Officer3.2.2025 15:30:00 EET | Press release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the appointment of Rob Wojciechowski as Chief Operations Officer (COO). In this new role, Rob will oversee the company’s strategic initiatives across its regulatory, quality, and compliance practice areas, further positioning ELIQUENT to meet the growing global demand for integrated regulatory, quality, and safety solutions across diverse markets. “Rob’s expertise in building consulting practices and fostering client relationships aligns with ELIQUENT’s commitment to delivering innovative, high-quality solutions to meet the evolving needs of clients,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences. A seasoned life sciences executive and Non-Executive Director (NED) board member, Rob brings an extensive background in leadership, strategic consulting, and global business growth. As COO, Rob will work closely with the ELIQUENT leadership team to strengthen the fi
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing3.2.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This milestone funding round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis.Additional support came from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others. Since its founding in June 2019, AdvanCell has grown from a belief in the potential of Targeted Alpha Therapy into a global organisation with 60 passionate team members, a 40,000-square-foot manufacturing facility, world-class pre-clinical infrastructure, a potentially best-in-class drug for prostate cancer that is in trials, and a deep and developing pipeline of assets. This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom